Hyperparathyroidism Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.A Trial of SHR6508 in Secondary Hyperparathyroidism
Condition: Secondary Hyperparathyroidism Intervention: Drug: SHR6508；Placebo Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2022 Category: Research Source Type: clinical trials
